Last updated: February 26, 2026
What Is NDC 69238-1204?
NDC 69238-1204 refers to a prescription drug with the following profile:
- Drug Name: Carbohydrate, Lipid, and Protein Intravenous (typically used in nutritional therapy)
- Manufacturer: Fresenius Kabi USA, LLC
- Formulation: A compounded or ready-to-use nutritional infusion
- Indications: Used for total parenteral nutrition (TPN) in hospital settings
This NDC code signifies a multi-component TPN formulation primarily administered intravenously in clinical environments.
Market Overview
Market Size
The global parenteral nutrition (PN) market was valued at approximately $4.8 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 6% between 2023 and 2028, driven by an aging population, increasing prevalence of gastrointestinal surgeries, and rising chronic diseases requiring nutritional support.[1]
Competitive Landscape
The market comprises multiple players offering both branded and compounded TPN solutions:
| Company |
Market Share |
Product Focus |
Key Distribution Channels |
| Fresenius Kabi |
45% |
Total parenteral nutrition |
Hospitals, outpatient clinics |
| Baxter International |
25% |
TPN and peripheral infusions |
Hospitals |
| B. Braun Medical |
15% |
Customized TPN solutions |
Hospitals, infusion centers |
| Others |
15% |
Nuanced formulations |
Regional distributors |
Major hospital systems purchase these products directly or through distributors, with compounded TPN remaining significant in some regions.
Usage Trends
- Hospital-Administered Nutrition: Predominant in acute, chronic, and pediatric care.
- Shift Toward Standardized Formulations: Hospitals shift from compounded to commercially prepared solutions for regulatory compliance and quality consistency.
- Demand Drivers: Increasing surgeries, cancer therapies, and prevalence of malnutrition in hospitalized patients.
Price Analysis
Current Pricing
- Brand-name TPN solutions: Approximately $65–$100 per 100 mL unit.
- Bulk procurement: Discounted rates of $40–$70 per 100 mL, depending on volume and payer negotiations.
- Compounded solutions: Typically cost between $25–$40 per 100 mL, depending on ingredients and institutional contracts.
Cost Variability
Factors impacting pricing include:
- Formulation complexity: Multi-component solutions with added electrolytes and drugs.
- Regulatory compliance: FDA-approved formulations cost more than compounded preparations.
- Supply chain factors: Inflation, material costs, and logistics can influence pricing.
Price Projections (2023–2028)
| Year |
Estimated Price per 100 mL |
Key Factors Influencing Price |
| 2023 |
$60–$85 |
Stable supply, moderate inflation |
| 2024 |
$62–$88 |
Rising raw material costs, regulatory costs |
| 2025 |
$65–$92 |
Increased demand, supply chain constraints |
| 2026 |
$68–$95 |
Market consolidation, inflationary pressure |
| 2027 |
$70–$98 |
Potential reimbursement adjustments, technological improvements |
| 2028 |
$72–$100 |
Market stabilization, inflation persists |
The upward trend stems from rising manufacturing costs, regulatory requirements, and increasing clinical demand.
Regulatory and Market Entry Considerations
- Approval Status: The product is approved as a sterile drug product by the FDA.
- Patent/IP: The formulation's patent status varies; specific compositions may have exclusivity periods.
- Market Entry Barriers: High manufacturing standards, regulatory hurdles, and established distribution channels favor incumbent firms.
Opportunities and Challenges
- Opportunities: Growing need in outpatient and home infusion markets; potential for biosimilar or generic formulations.
- Challenges: Price competition from compounded solutions; regulatory scrutiny; supply chain disruptions.
Key Takeaways
- The TPN market, including products like NDC 69238-1204, is expanding with a CAGR of around 6% driven by clinical and demographic trends.
- Pricing per 100 mL is currently $60–$85 with a projected increase to almost $100 by 2028.
- Dominated by large firms such as Fresenius Kabi and Baxter, with significant hospital-based sales.
- Advancements in formulations and supply chain optimization could influence future pricing and market share dynamics.
- Regulatory compliance and product differentiation are critical competitive advantages.
FAQs
1. What factors will most influence the price of NDC 69238-1204 over the next five years? Cost of raw materials, regulatory compliance costs, and supply chain stability will be primary drivers.
2. Are there imminent regulatory changes affecting this product? Ongoing FDA oversight of sterile injectable products could influence manufacturing standards and pricing.
3. What role will generic or biosimilar versions play? Entering the market as affordable alternatives, biosimilars or generics could pressure prices downward post patent expiry.
4. How does hospital procurement impact pricing? Bulk purchasing agreements and long-term contracts typically reduce per-unit costs.
5. Is the market shifting toward outpatient or home infusion delivery? Yes, increasing access to outpatient infusion therapy is expected to expand market opportunities.
References
[1] Markets and Markets. (2022). Parenteral Nutrition Market by Product, Application, End User, and Region.
